Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | PDE5A | O76074 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.58 |
| ▸ | PDE1A | P54750 | 1/20 | 0.55 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.55 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.55 |
| ▸ | SCD | O00767 | 1/20 | 0.55 |
| ▸ | KDM4A | O75164 | 1/20 | 0.54 |
| ▸ | KDM4B | O94953 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91391 | 0.86 | KDM4E (0.69) | KDM4EPDE5ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2227204 | 0.83 | KDM4E (0.69) | KDM4EPDE5ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2664517 | 0.83 | KDM4E (0.69) | KDM4EPDE5ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27599948 | 0.83 | KDM4E (0.78) | KDM4EPDE5ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6919140 | 0.82 | KDM4E (0.64) | KDM4EPDE5ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL367981 | 0.82 | SMN1; SMN2 (0.51) | KDM4EPDE5ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5717620 | 0.81 | KDM4E (0.74) | KDM4EPDE5ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27782868 | 0.81 | AOC3 (0.74) | KDM4EPDE5ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27782870 | 0.80 | SMN1; SMN2 (0.62) | KDM4EPDE5ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3653731 | 0.80 | ROCK2 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | KDM4E 2280/4885PDE5A 1080/4885NPC1 1139/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | KDM4E 2280/4885PDE5A 1080/4885NPC1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.